Musheng Bao

Musheng Bao

Company: Harbour Biomed

Job title: Senior Director


HBM1007, A Fully Human CD73 Antibody With Allosteric Inhibition & Strong Internalization Mediated Target Downregulation For Cancer Therapy 4:15 pm

• Highlighting HMB1007 binds to a unique epitope of CD73 and shows high binding affinity to human and Cyno CD73 • Understanding HBM1007 demonstrates irreversible CD73 enzymatic blocking activity and induces CD73 endocytosis and degradation • Divulging that HBM1007 achieves synergistic anti-tumor efficacy with anti-PD-1 or anti-CTLA-4 Abs • HBM1007 shows good safety and developability…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.